IL18 and neoplasm: They demonstrated that GzB-IL18 enhances the efficacy of αβ and γδ CAR T cell immunotherapy in a tumor-dependent manner and that GzB-IL18 provides a highly effective armoring strategy for γδ CAR T cells.